Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia

Bruey, Jean Marie; Kantarjian, Hagop M.; Estrov, Zeev; Zhang, Zhong; Ma, Wanlong; Albitar, Ferras; Abdool, Adam; Thomas, Deborah A.; Yeh, Chen‐Hsiung; O’Brien, Susan; Albitar, Mäher

doi:10.1016/j.leukres.2009.07.030

Cited by 12 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assay specificity, sensitivity and accuracy have been previously reported [15]. Figure 1 shows the levels of Ki-67 protein as detected by immunoprecipitation and Western blot (panel A) and as detected by the ECL assay (panel B).…”

Section: Resultsmentioning

confidence: 71%

“…The correlation between low Ki-67 index and histologically low-grade tumors is strong [9, 11, 25-35]. Our recent report [36] demonstrated that plasma cKi-67 levels can be used as a biomarker in ALL, and that the only functional difference between the plasma cKi-67 assay and the IHC Ki-67 index assay is that the former lacks normalization to the number of tumor cells. Plasma levels of cKi-67 could reflect variation in not only tumor mass, but also in levels of tumor proliferation and aggressiveness.…”

Section: Discussionmentioning

confidence: 99%

“…This assay employs an ECL-based technology from MSD, an adaptation of enzyme-linked immunosorbent assays (ELISAs), as described previously[14]. …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

Bruey

Kantarjian

et al. 2010

Leukemia Research

Self Cite

View full text Add to dashboard Cite

Ki-67 is a nuclear antigen that is expressed in all stages of the cell cycle, except G0, and is widely used as a marker of cellular proliferation in human tumors. We recently showed that elevated levels of Ki-67 circulating in plasma (cKi-67) are associated with shorter survival in patients with acute lymphoblastic leukemia. The study included 194 patients with CLL and 96 healthy control subjects. cKi-67 levels in plasma were determined using an electrochemiluminescent immunoassay. We normalized the cKi-67 level to the absolute number of lymphocytes in the patient's peripheral blood to establish the plasma cKI-67 index. The cKi-67 index showed significant correlation with lymph node involvement and Rai stage (P = 0.05). Higher cKi-67 index values were significantly associated with shorter survival. Multivariate Cox proportional hazards regression analysis demonstrated that the association of the cKi-67 index with shorter survival was independent of IgVH mutation status. In a multivariate model incorporating the cKi-67 index with B2M and IgVH, only cKi-67 index and B2M levels remained as independent predictors of survival. The results of this study suggest that the plasma cKi-67 index, along with B2M level, is a strong predictor of clinical behavior in CLL

show abstract

Section: Resultsmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

Bruey

Kantarjian

et al. 2010

Leukemia Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bettina Ferro de Souza University Hospital -Hospital Complex of UFPA (CHU-UFPA), Belém -PA *E-mail: luigisilva1@gmail.com 2 University Center of Pará (CESUPA), Belém -PA 3. João Barros Barreto University Hospital -Hospital Complex of UFPA (CHU-UFPA), Belém -PA.…”

mentioning

confidence: 99%

Desmoid tumor of the neck: a case report

Silva¹,

Franco²,

Freire³

et al. 2020

Acervo Saúde

View full text Add to dashboard Cite

Objective: To report a case of Desmoid Tumor in the cervical region. Case Report: A case of a large mass in the cervical region of a patient with progressive growth, neck pain and some move restriction, without other comorbidities. Imaging, histopathologic and immunohistochemical study were needed for diagnosis, surgical treatment and postoperative care. Imaging showed a 12.6 x 5.7 x 5.8cm tumor, T1-weighted muscle isointense and T2-weighted hyperintense heterogeneous core, close to paravertebral muscles and pushing left sternocleidomastoid muscle laterally. The chosen treatment was complete tumor exeresis. Immunohistochemistry revealed myofibroblastic neoplasm compatible with desmoid fibromatosis with positivity for nuclear beta-catenin. Final Considerations: Large benign and infiltrative tumors need to be well conducted. It is essential that otolaryngologists are aware of the nature of these cases, differential diagnosis, treatment options and their possible complications, because eventually cases like this may appear requiring special care.

show abstract

“…In this issue Bruey et al, describe an electrochemical based enzyme immunoassay which detects Ki-67 in plasma [6]. This is the first report of an assay which monitors circulating levels of this protein.…”

mentioning

confidence: 99%

Development of a bioassay to monitor circulating plasma Ki-67

Hardiman

2010

Leukemia Research

View full text Add to dashboard Cite

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia

Cited by 12 publications

References 25 publications

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

Desmoid tumor of the neck: a case report

Development of a bioassay to monitor circulating plasma Ki-67

Contact Info

Product

Resources

About